The selected HS-binding peptide interacts with a specific structure of heparan sulfate and inhibits tumor growth of triple-negative breast cancer cells, possibly interfering with the proliferation signaling modulated by FGF-2 and consequently decreasing angiogenesis. Here, FGF2 is linked to triple-negative breast carcinoma.